BIOGEN INC (IDP.DE) Fundamental Analysis & Valuation

FRA:IDP • US09062X1037

156.7 EUR
-5.55 (-3.42%)
Last: Mar 6, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This IDP.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to IDP. IDP was compared to 75 industry peers in the Biotechnology industry. IDP is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. IDP has a bad growth rate and is valued cheaply. With these ratings, IDP could be worth investigating further for value investing!.


Dividend Valuation Growth Profitability Health

6

1. IDP.DE Profitability Analysis

1.1 Basic Checks

  • In the past year IDP was profitable.
  • In the past year IDP had a positive cash flow from operations.
  • Each year in the past 5 years IDP has been profitable.
  • Each year in the past 5 years IDP had a positive operating cash flow.
IDP.DE Yearly Net Income VS EBIT VS OCF VS FCFIDP.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

1.2 Ratios

  • The Return On Assets of IDP (4.39%) is better than 78.67% of its industry peers.
  • IDP has a better Return On Equity (7.08%) than 80.00% of its industry peers.
  • IDP's Return On Invested Capital of 8.93% is amongst the best of the industry. IDP outperforms 84.00% of its industry peers.
  • IDP had an Average Return On Invested Capital over the past 3 years of 8.93%. This is below the industry average of 12.19%.
  • The last Return On Invested Capital (8.93%) for IDP is above the 3 year average (8.93%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 4.39%
ROE 7.08%
ROIC 8.93%
ROA(3y)4.85%
ROA(5y)6.69%
ROE(3y)8.23%
ROE(5y)12.34%
ROIC(3y)8.93%
ROIC(5y)10.93%
IDP.DE Yearly ROA, ROE, ROICIDP.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40

1.3 Margins

  • IDP's Profit Margin of 13.07% is fine compared to the rest of the industry. IDP outperforms 80.00% of its industry peers.
  • In the last couple of years the Profit Margin of IDP has declined.
  • With an excellent Operating Margin value of 27.94%, IDP belongs to the best of the industry, outperforming 85.33% of the companies in the same industry.
  • In the last couple of years the Operating Margin of IDP has declined.
  • IDP has a better Gross Margin (75.69%) than 66.67% of its industry peers.
  • In the last couple of years the Gross Margin of IDP has declined.
Industry RankSector Rank
OM 27.94%
PM (TTM) 13.07%
GM 75.69%
OM growth 3Y-3.78%
OM growth 5Y-5.27%
PM growth 3Y-24.15%
PM growth 5Y-15.17%
GM growth 3Y-0.7%
GM growth 5Y-2.57%
IDP.DE Yearly Profit, Operating, Gross MarginsIDP.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. IDP.DE Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), IDP is creating some value.
  • The number of shares outstanding for IDP has been increased compared to 1 year ago.
  • Compared to 5 years ago, IDP has less shares outstanding
  • Compared to 1 year ago, IDP has an improved debt to assets ratio.
IDP.DE Yearly Shares OutstandingIDP.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
IDP.DE Yearly Total Debt VS Total AssetsIDP.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B 25B

2.2 Solvency

  • An Altman-Z score of 3.34 indicates that IDP is not in any danger for bankruptcy at the moment.
  • With a decent Altman-Z score value of 3.34, IDP is doing good in the industry, outperforming 69.33% of the companies in the same industry.
  • The Debt to FCF ratio of IDP is 3.11, which is a good value as it means it would take IDP, 3.11 years of fcf income to pay off all of its debts.
  • With an excellent Debt to FCF ratio value of 3.11, IDP belongs to the best of the industry, outperforming 84.00% of the companies in the same industry.
  • IDP has a Debt/Equity ratio of 0.34. This is a healthy value indicating a solid balance between debt and equity.
  • IDP has a Debt to Equity ratio (0.34) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF 3.11
Altman-Z 3.34
ROIC/WACC1.1
WACC8.11%
IDP.DE Yearly LT Debt VS Equity VS FCFIDP.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.3 Liquidity

  • IDP has a Current Ratio of 2.68. This indicates that IDP is financially healthy and has no problem in meeting its short term obligations.
  • IDP has a Current ratio of 2.68. This is comparable to the rest of the industry: IDP outperforms 57.33% of its industry peers.
  • IDP has a Quick Ratio of 2.03. This indicates that IDP is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 2.03, IDP perfoms like the industry average, outperforming 49.33% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.68
Quick Ratio 2.03
IDP.DE Yearly Current Assets VS Current LiabilitesIDP.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. IDP.DE Growth Analysis

3.1 Past

  • The earnings per share for IDP have decreased by -7.16% in the last year.
  • The earnings per share for IDP have been decreasing by -14.17% on average. This is quite bad
  • The Revenue has been growing slightly by 2.22% in the past year.
  • IDP shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -5.96% yearly.
EPS 1Y (TTM)-7.16%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%-42.15%
Revenue 1Y (TTM)2.22%
Revenue growth 3Y-0.93%
Revenue growth 5Y-5.96%
Sales Q2Q%-7.14%

3.2 Future

  • IDP is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.54% yearly.
  • IDP is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.42% yearly.
EPS Next Y-0.5%
EPS Next 2Y2.48%
EPS Next 3Y3.07%
EPS Next 5Y3.54%
Revenue Next Year-3.97%
Revenue Next 2Y-2.47%
Revenue Next 3Y-1.27%
Revenue Next 5Y-0.42%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IDP.DE Yearly Revenue VS EstimatesIDP.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B
IDP.DE Yearly EPS VS EstimatesIDP.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

7

4. IDP.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 11.91, the valuation of IDP can be described as very reasonable.
  • 92.00% of the companies in the same industry are more expensive than IDP, based on the Price/Earnings ratio.
  • When comparing the Price/Earnings ratio of IDP to the average of the S&P500 Index (26.29), we can say IDP is valued rather cheaply.
  • Based on the Price/Forward Earnings ratio of 11.97, the valuation of IDP can be described as reasonable.
  • Based on the Price/Forward Earnings ratio, IDP is valued cheaply inside the industry as 97.33% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of IDP to the average of the S&P500 Index (24.57), we can say IDP is valued rather cheaply.
Industry RankSector Rank
PE 11.91
Fwd PE 11.97
IDP.DE Price Earnings VS Forward Price EarningsIDP.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • 90.67% of the companies in the same industry are more expensive than IDP, based on the Enterprise Value to EBITDA ratio.
  • IDP's Price/Free Cash Flow ratio is rather cheap when compared to the industry. IDP is cheaper than 94.67% of the companies in the same industry.
Industry RankSector Rank
P/FCF 13.23
EV/EBITDA 8.28
IDP.DE Per share dataIDP.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60 80 100

4.3 Compensation for Growth

  • IDP has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.48%
EPS Next 3Y3.07%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IDP.DE Dividend Analysis

5.1 Amount

  • IDP does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IDP.DE Fundamentals: All Metrics, Ratios and Statistics

BIOGEN INC

FRA:IDP (3/6/2026, 7:00:00 PM)

156.7

-5.55 (-3.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-06
Earnings (Next)04-29
Inst Owners96.04%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap23.00B
Revenue(TTM)9.89B
Net Income(TTM)1.29B
Analysts73.33
Price Target177.03 (12.97%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.18%
Min EPS beat(2)20.87%
Max EPS beat(2)21.48%
EPS beat(4)4
Avg EPS beat(4)24.64%
Min EPS beat(4)17.28%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)17.2%
EPS beat(12)12
Avg EPS beat(12)12.76%
EPS beat(16)15
Avg EPS beat(16)12.81%
Revenue beat(2)2
Avg Revenue beat(2)3.75%
Min Revenue beat(2)1.26%
Max Revenue beat(2)6.23%
Revenue beat(4)4
Avg Revenue beat(4)6.45%
Min Revenue beat(4)1.26%
Max Revenue beat(4)11.62%
Revenue beat(8)6
Avg Revenue beat(8)2.98%
Revenue beat(12)9
Avg Revenue beat(12)2.26%
Revenue beat(16)11
Avg Revenue beat(16)1.92%
PT rev (1m)8.48%
PT rev (3m)14.26%
EPS NQ rev (1m)-13.19%
EPS NQ rev (3m)-11.95%
EPS NY rev (1m)-1.51%
EPS NY rev (3m)-2.56%
Revenue NQ rev (1m)-1.38%
Revenue NQ rev (3m)-0.78%
Revenue NY rev (1m)1.15%
Revenue NY rev (3m)1.7%
Valuation
Industry RankSector Rank
PE 11.91
Fwd PE 11.97
P/S 2.7
P/FCF 13.23
P/OCF 12.12
P/B 1.46
P/tB 10.33
EV/EBITDA 8.28
EPS(TTM)13.16
EY8.4%
EPS(NY)13.09
Fwd EY8.36%
FCF(TTM)11.84
FCFY7.56%
OCF(TTM)12.93
OCFY8.25%
SpS58.01
BVpS107.07
TBVpS15.17
PEG (NY)N/A
PEG (5Y)N/A
Graham Number178.06
Profitability
Industry RankSector Rank
ROA 4.39%
ROE 7.08%
ROCE 10.59%
ROIC 8.93%
ROICexc 10.46%
ROICexgc 35.29%
OM 27.94%
PM (TTM) 13.07%
GM 75.69%
FCFM 20.42%
ROA(3y)4.85%
ROA(5y)6.69%
ROE(3y)8.23%
ROE(5y)12.34%
ROIC(3y)8.93%
ROIC(5y)10.93%
ROICexc(3y)9.96%
ROICexc(5y)13.03%
ROICexgc(3y)38.5%
ROICexgc(5y)36.85%
ROCE(3y)10.59%
ROCE(5y)12.95%
ROICexgc growth 3Y4.85%
ROICexgc growth 5Y-4.35%
ROICexc growth 3Y-13.95%
ROICexc growth 5Y-14.37%
OM growth 3Y-3.78%
OM growth 5Y-5.27%
PM growth 3Y-24.15%
PM growth 5Y-15.17%
GM growth 3Y-0.7%
GM growth 5Y-2.57%
F-Score4
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF 3.11
Debt/EBITDA 1.77
Cap/Depr 23.77%
Cap/Sales 1.87%
Interest Coverage 10.46
Cash Conversion 62.22%
Profit Quality 156.18%
Current Ratio 2.68
Quick Ratio 2.03
Altman-Z 3.34
F-Score4
WACC8.11%
ROIC/WACC1.1
Cap/Depr(3y)46.72%
Cap/Depr(5y)49.51%
Cap/Sales(3y)2.92%
Cap/Sales(5y)2.77%
Profit Quality(3y)138.91%
Profit Quality(5y)133.83%
High Growth Momentum
Growth
EPS 1Y (TTM)-7.16%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%-42.15%
EPS Next Y-0.5%
EPS Next 2Y2.48%
EPS Next 3Y3.07%
EPS Next 5Y3.54%
Revenue 1Y (TTM)2.22%
Revenue growth 3Y-0.93%
Revenue growth 5Y-5.96%
Sales Q2Q%-7.14%
Revenue Next Year-3.97%
Revenue Next 2Y-2.47%
Revenue Next 3Y-1.27%
Revenue Next 5Y-0.42%
EBIT growth 1Y8.4%
EBIT growth 3Y-4.68%
EBIT growth 5Y-10.91%
EBIT Next Year16.69%
EBIT Next 3Y5.17%
EBIT Next 5Y1.28%
FCF growth 1Y-19.74%
FCF growth 3Y20.95%
FCF growth 5Y-11.3%
OCF growth 1Y-23.33%
OCF growth 3Y16.78%
OCF growth 5Y-12.22%

BIOGEN INC / IDP.DE FAQ

What is the ChartMill fundamental rating of BIOGEN INC (IDP.DE) stock?

ChartMill assigns a fundamental rating of 5 / 10 to IDP.DE.


What is the valuation status for IDP stock?

ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (IDP.DE). This can be considered as Undervalued.


What is the profitability of IDP stock?

BIOGEN INC (IDP.DE) has a profitability rating of 6 / 10.


What is the financial health of BIOGEN INC (IDP.DE) stock?

The financial health rating of BIOGEN INC (IDP.DE) is 7 / 10.


What is the expected EPS growth for BIOGEN INC (IDP.DE) stock?

The Earnings per Share (EPS) of BIOGEN INC (IDP.DE) is expected to decline by -0.5% in the next year.